Literature DB >> 382002

Common aspects of immunologic tolerance in pregnancy and malignancy.

N Gleicher, G Deppe, C J Cohen.   

Abstract

The fetoplacental allograft and the malignant neoplasm represent the only 2 biologic conditions in which antigenic tissue is tolerated by a seemingly intact immune system. Recent investigations in the fields of tumor and pregnancy immunology have resulted in the recognition of a variety of immunologic mechanisms which are common to both systems. These common denominators are reviewed and a thesis suggesting a common mechanism in the nonrejection of pregnancy and malignancy, based on the presence of embryonic antigens in both systems, is presented.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 382002

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

1.  Prognosis in gastric cancer associated with pregnancy.

Authors:  H Ueo; H Matsuoka; S Tamura; K Sato; Y Tsunematsu; T Kato
Journal:  World J Surg       Date:  1991 Mar-Apr       Impact factor: 3.352

2.  A dioestrous increase in thymocyte proliferation during the oestrous cycle.

Authors:  O Habbal; G Leeming; E T Morgan; J M McLean
Journal:  Experientia       Date:  1987-09-15

3.  Chondroma of the Sternum Growing in a Pregnant Patient: A Case Report.

Authors:  Stefanie Braun; Henner Weichhardt; Dirk Uhlmann
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-06-07       Impact factor: 1.520

4.  The uncertain science of preimplantation and prenatal genetic testing.

Authors:  Norbert Gleicher; David F Albertini; Pasquale Patrizio; Raoul Orvieto; Eli Y Adashi
Journal:  Nat Med       Date:  2022-03       Impact factor: 87.241

5.  Autoimmune thyroid disease in the puerperium. Predictive value of thyroid enlargement and related hormonal changes occurring during pregnancy.

Authors:  C Fardella; J M López; M E Valdés; M Nuñez; M Miranda
Journal:  J Endocrinol Invest       Date:  1990-04       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.